Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes that have long-term impact and cost-of-care implications: cardiovascular death, kidney failure and hospitalization for heart failure.

https://investor.lilly.com/releasedetail.cfm?ReleaseID=1041519

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom (NYSE:LLY)

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom (NYSE:LLY)

Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine (NYSE:LLY)

INDIANAPOLIS, May 12, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) demonstrating statistically significant reductions in the number of monthly migraine headache days compared to placebo at both studied doses.



Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine (NYSE:LLY)

Lilly to Participate in Bernstein Strategic Decisions Conference (NYSE:LLY)

Lilly to Participate in Bernstein Strategic Decisions Conference (NYSE:LLY)

Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications (NYSE:LLY)

Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications (NYSE:LLY)

Lilly to Participate in UBS Global Healthcare Conference (NYSE:LLY)

Lilly to Participate in UBS Global Healthcare Conference (NYSE:LLY)

Lilly Announces Webcast to Discuss Oncology Pipeline (NYSE:LLY)

Lilly Announces Webcast to Discuss Oncology Pipeline (NYSE:LLY)

Lilly Declares Second-Quarter 2017 Dividend (NYSE:LLY)

Lilly Declares Second-Quarter 2017 Dividend (NYSE:LLY)

Lilly Reports First-Quarter 2017 Results (NYSE:LLY)

Lilly Reports First-Quarter 2017 Results (NYSE:LLY)

U.S. FDA Issues Complete Response Letter for Baricitinib (NYSE:LLY)

INDIANAPOLIS--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA).



U.S. FDA Issues Complete Response Letter for Baricitinib (NYSE:LLY)

Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences (NYSE:LLY)

Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences (NYSE:LLY)

Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (NYSE:LLY)

Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (NYSE:LLY)

Lilly to Present at Cowen Health Care Conference (NYSE:LLY)

Lilly to Present at Cowen Health Care Conference (NYSE:LLY)

Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes (NYSE:LLY)

INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity^® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The U.S. Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is available in a prefilled pen in 0.75 and 1.5 mg doses.



Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes (NYSE:LLY)

Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (NYSE:LLY)

Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (NYSE:LLY)